BR112022012917A2 - Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica - Google Patents
Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópicaInfo
- Publication number
- BR112022012917A2 BR112022012917A2 BR112022012917A BR112022012917A BR112022012917A2 BR 112022012917 A2 BR112022012917 A2 BR 112022012917A2 BR 112022012917 A BR112022012917 A BR 112022012917A BR 112022012917 A BR112022012917 A BR 112022012917A BR 112022012917 A2 BR112022012917 A2 BR 112022012917A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- topical composition
- disorder
- jak
- mucosal
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000000699 topical effect Effects 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 239000004012 Tofacitinib Substances 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 229960000556 fingolimod Drugs 0.000 abstract 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 abstract 1
- 229960001350 tofacitinib Drugs 0.000 abstract 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 abstract 1
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMPOSIÇÃO TÓPICA, KIT, MÉTODOS PARA TRATAR OU MELHORAR UM DISTÚRBIO DA PELE, DE MUCOSA, DE CAVIDADE CORPORAL, MÉTODO PARA TRATAR UMA CONDIÇÃO RELACIONADA A JAK, MÉTODO PARA TRATAR OU PREVENIR UM DISTÚRBIO DERMATOLÓGICO, E, USO DA COMPOSIÇÃO TÓPICA. A presente invenção se refere a novas formulações tópicas contendo um tofacitinibe e ou uma fingolimode que são úteis para tratar condições dermatológicas, tal como dermatite atópica, psoríase e eczema.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962955847P | 2019-12-31 | 2019-12-31 | |
US202063066717P | 2020-08-17 | 2020-08-17 | |
US202063086275P | 2020-10-01 | 2020-10-01 | |
US202063086442P | 2020-10-01 | 2020-10-01 | |
PCT/US2020/067612 WO2021138525A1 (en) | 2019-12-31 | 2020-12-31 | Topical composition comprising tofacitinib and fingolimod |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022012917A2 true BR112022012917A2 (pt) | 2022-09-06 |
Family
ID=74285586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022012917A BR112022012917A2 (pt) | 2019-12-31 | 2020-12-31 | Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230037905A1 (pt) |
EP (1) | EP4084776A1 (pt) |
JP (1) | JP2023509441A (pt) |
AU (1) | AU2020417290A1 (pt) |
BR (1) | BR112022012917A2 (pt) |
CA (1) | CA3163530A1 (pt) |
IL (1) | IL294239A (pt) |
TW (1) | TW202135825A (pt) |
WO (1) | WO2021138525A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10960006B2 (en) * | 2018-01-31 | 2021-03-30 | Twi Pharmaceuticals, Inc. | Topical formulations comprising tofacitinib |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4874794A (en) | 1989-04-28 | 1989-10-17 | Lidak Biopharmaceuticals | Inflammatory disease treatment |
EP3065717A1 (en) | 2013-11-04 | 2016-09-14 | Biopharmx, Inc. | Dosage form comprising an active ingredient and a plurality of solid porous microcarriers |
-
2020
- 2020-12-31 EP EP20845858.8A patent/EP4084776A1/en active Pending
- 2020-12-31 WO PCT/US2020/067612 patent/WO2021138525A1/en unknown
- 2020-12-31 IL IL294239A patent/IL294239A/en unknown
- 2020-12-31 JP JP2022540904A patent/JP2023509441A/ja active Pending
- 2020-12-31 TW TW109147197A patent/TW202135825A/zh unknown
- 2020-12-31 AU AU2020417290A patent/AU2020417290A1/en active Pending
- 2020-12-31 CA CA3163530A patent/CA3163530A1/en active Pending
- 2020-12-31 US US17/758,175 patent/US20230037905A1/en active Pending
- 2020-12-31 BR BR112022012917A patent/BR112022012917A2/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2021138525A1 (en) | 2021-07-08 |
IL294239A (en) | 2022-08-01 |
EP4084776A1 (en) | 2022-11-09 |
CA3163530A1 (en) | 2021-07-08 |
TW202135825A (zh) | 2021-10-01 |
AU2020417290A1 (en) | 2022-05-26 |
US20230037905A1 (en) | 2023-02-09 |
JP2023509441A (ja) | 2023-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022002413A2 (es) | Composiciones y métodos para tratar la psoriasis y la dermatitis atópica usando prevotella histicola | |
CL2019002255A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas. | |
MX2019003397A (es) | Metodos para tratar trastornos mitocondriales y metabolicos. | |
BR112014026058A2 (pt) | composições para tratamento tópico de infecções microbianas | |
MX2020012018A (es) | Composiciones para el tratamiento de condiciones de la piel. | |
MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
CR20220207A (es) | Compuestos terapéuticos y métodos de uso | |
MX2019002047A (es) | Metodos y composiciones para tratar infecciones fungicas cutaneas. | |
BR112016024621A2 (pt) | composições para tratamento bucal | |
ECSP23096498A (es) | Restos de administración terapéutica novedosos y usos de estos | |
MX2022012692A (es) | Composiciones que comprenden nanoparticulas, metodo de elaboracion y usos de las mismas. | |
CL2023000921A1 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead | |
BR112022012917A2 (pt) | Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica | |
BR112022003659A2 (pt) | Composições e métodos de tratamento de doenças vasculares | |
BR112021009616A8 (pt) | Composição cicatrizante que compreende água eletrolisada e máscara de aplicação cutânea | |
MX2021003527A (es) | Tratamiento de baja intensidad de trastornos hematologicos. | |
CL2019001338A1 (es) | Preparación cosmética de viscosidad mejorada para el tratamiento de las fibras queratínicas, proceso para el aumento de la viscosidad de una preparación cosmética, uso de ingredientes modificadores de la viscosidad y método de tratamiento de las fibras queratínicas. | |
BR112018000589A2 (pt) | composição de tratamento de cabelo, método para o tratamento de cabelo e utilização de uma composição | |
BR112021021676A2 (pt) | Uso de preparação de exossomo de células-tronco mesenquimais para a preparação de composição para o tratamento da doença periodontal | |
MX2020000681A (es) | Tirotricina para usarse en el tratamiento o profilaxis del olor corporal, y preparaciones de la misma. | |
BR112023021510A2 (pt) | Métodos de tratamento de estenoses esofágicas | |
MX2019000006A (es) | Composiciones para el tratamiento de estrias y ulceras de origen isquemico. | |
ZA202204938B (en) | Enhancement and stabilisation of proteolytic activity of proteases | |
BR112015020182A2 (pt) | uso cosmético de queuina ou de um precursor ou um derivado dessa como ingrediente ativo, uso de queuina ou um precursor ou um derivado dessa como ingrediente ativo, composição cosmética e processo de tratamento cosmético para prevenir e/ou tratar sinais de envelhecimento da pele e/ou anexos cutâneos | |
CL2022000317A1 (es) | Composición cosmética tópica, uso de la composición cosmética y máscara para aplicación facial |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |